Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE0005659700
Wed, 19.06.2024
Eckert & Ziegler SE
June 19, 2024 – Berlin, Germany and Řež, Czech Republic – Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler), in collaboration with the Nuclear Physics Institute of the Czech Academy of Sciences (Ústav jaderné fyziky, “UJF”), announces the grand opening of a pioneering Actinium-225 (Ac-225) production facility. This milestone, celebrated [ … ]
Fri, 31.05.2024
Eckert & Ziegler SE
BOSTON, Mass., May 31, 2024 – Eckert & Ziegler reports about the successful completion of the 2nd annual Boston Radionuclide Theranostics Forum, reaffirming its pivotal role in the field of radiopharmaceuticals. Building on the momentum of last year's inaugural event, the Forum once again brought together leading experts, potential and existing [ … ]
Fri, 24.05.2024
Eckert & Ziegler SE
Berlin, 24 May 2024. Eckert & Ziegler SE (ISIN DE0005659700) was honored with the “Best Managed Companies Award” at an award ceremony in Frankfurt am Main on May 23, 2024. With this award, Deloitte Private, UBS, Frankfurter Allgemeine Zeitung and the Federation of German Industries (Bundesverband der Deutschen Industrie e.V.) recognize outstand [ … ]
Tue, 14.05.2024
Eckert & Ziegler SE
1st Quarter 2024:
Sales of € 67.6 million (previous year: € 57.9 million)
EBIT before special items of € 15.0 million (previous year: € 10.6 million)
Net income € 8.5 million (previous year: € 4.7 million)
Forecast FY 2024:
Sales of just under € 265 Mio. (confirmed)
EBIT before special items of around € 50 million (confirmed)
Berlin, 14 May 2 [ … ]
Fri, 22.03.2024
Eckert & Ziegler SE
Berlin, March 22, 2024 - Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) generated sales of € 246.1 million in the 2023 financial year. Compared to the previous year, sales increased by € 23.8 million or 11%. EBIT from continuing operations before special items reached € 46.9 million. Net profit for the year amounted to € 26.3 million correspon [ … ]
Thu, 21.03.2024
Eckert & Ziegler SE
Berlin, Germany – 21 March 2024 – Eckert & Ziegler BEBIG GmbH, subsidiary of Eckert & Ziegler SE with focus on brachytherapy solutions for the treatment of prostate cancer as well as eye and brain tumors, obtained the MDR certificate for its proprietary prostate seeds from DEKRA Certification B.V. as one of the first companies in its market [ … ]
Tue, 19.03.2024
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 19.03.2024. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) today completed its change of legal form to a Societas Europaea (SE) with entry in the company's commercial register and will in future operate as Eckert & Ziegler SE.
Eckert & Ziegler SE has a dualistic management system consisting of a management [ … ]
Wed, 28.02.2024
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, Germany – 28 February 2024 – Eckert & Ziegler (ISIN DE0005659700, SDAX) expands its activities on Gallium-68 (Ga-68) labeled diagnostics in Japan together with Novartis Pharma K.K. (Japan). For this purpose, a clinical trial was notified with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA), stating Eckert & Ziegler’s [ … ]
Wed, 31.01.2024
Eckert & Ziegler Strahlen- und Medizintechnik AG
Eckert & Ziegler's supply of Lu-177 and Ac-225 enables Nucleus Radiopharma entering a new era in cancer care
Berlin, Germany and Rochester, MN, USA – January 31, 2024 – Eckert & Ziegler (ISIN DE0005659700, SDAX) and Nucleus Radiopharma (Nucleus) signed extensive supply agreements for major therapeutic radioisotopes. Eckert & Ziegler wi [ … ]
Tue, 23.01.2024
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, Germany and Gembloux, Belgium – 23 January 2024 – Eckert & Ziegler (ISIN DE0005659700, SDAX) and Full-Life Technologies (Full-Life), a clinical stage, fully integrated global radiotherapeutics company today announced they have entered into an agreement for the supply of Actinium-225 (Ac-225). The agreement provides Full-Life with access [ … ]